idiopathic pulmonary fibrosis
Respiratory · 2015–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nintedanib Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with a progressive phenotype (PF-ILD). | Nov 2024 | Noted | input received |
| pirfenidone Treatment of idiopathic pulmonary fibrosis (IPF). This submission concerned new tablet formulations (267 mg and 801 mg) as alternatives to the previously… | Mar 2018 | Recommended with restriction | none received |
| pirfenidone Idiopathic pulmonary fibrosis (IPF) in patients with confirmed diagnosis, FVC ≥50% predicted, and DLCO ≥30% predicted. | Mar 2016 | Recommended with restriction | 1 individuals |
| nintedanib Treatment of patients with idiopathic pulmonary fibrosis (IPF), specifically mild to moderate IPF in patients meeting pulmonary function criteria. | Nov 2016 | Recommended with restriction | 33 individuals Lung Foundation Australia |
| pirfenidone Treatment of idiopathic pulmonary fibrosis (IPF) in adults with confirmed diagnosis, FVC ≥50% predicted, and DLCO ≥30% predicted. | Nov 2016 | Deferred | 50 individuals Lung Foundation Australia |
| nintedanib Treatment of idiopathic pulmonary fibrosis (IPF), a non-neoplastic irreversible fatal lung disease resulting from abnormal remodelling of lung tissue leading… | Mar 2015 | Not recommended | 3 individuals |
| nintedanib Treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in patients aged 40 years or older with confirmed diagnosis and specific lung function… | Nov 2015 | Deferred | 50 individuals Lung Foundation Australia · Lung Foundation |
| pirfenidone Treatment of idiopathic pulmonary fibrosis (IPF). Patients aged 40 years or older with confirmed IPF diagnosis, FVC ≥50% predicted, and DL_CO ≥30% predicted. | Nov 2015 | Not recommended | 48 individuals Lung Foundation Australia · Lung Foundation |
Who spoke
Lung Foundation Australia · Lung Foundation
What the PBS pays
$95M in government benefit over 2024–25, across 46,078 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nintedanib | $87M |
| pirfenidone | $7.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 3 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| nintedanibNintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | recommended restricted | 2023-02 |
| pirfenidonePirfenidone for treating idiopathic pulmonary fibrosis | TA504 | recommended restricted | 2018-02 |
| nintedanibNintedanib for treating idiopathic pulmonary fibrosis | TA379 | recommended restricted | 2016-01 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.